CELL THERAPY CATAPULT LIMITED

Their core work

Cell Therapy Catapult is a UK-based centre that accelerates the development and commercialization of cell and gene therapies — advanced therapy medicinal products (ATMPs). They bridge the gap between laboratory research and clinical manufacturing, contributing expertise in stem cell manufacturing, tissue engineering, and regulatory pathway navigation. Their work spans from automated cell production systems to public communication about gene and cell therapies, positioning them as a translational enabler for the advanced therapies sector.

What they specialise in

How they've shifted over time

Their early work (2016–2018) centred on physical tissue engineering — building scaffolds, seeding stem cells onto tracheas, and automating cell manufacturing processes. From 2019 onward, their focus shifted decisively toward immunomodulation and gene editing, with RESHAPE introducing CRISPR/Cas9, CAR-Treg, and humanized disease models. Most recently (2021+), they expanded into science communication and public engagement around gene and cell therapies through EuroGCT.

Moving from physical cell-based products toward genetically engineered immune cell therapies and broader ecosystem-building through public engagement — expect future projects at the CRISPR/immunotherapy intersection.

How they like to work

Cell Therapy Catapult consistently joins projects as a specialist participant rather than leading consortia — all five H2020 projects are in partner roles. They work within large consortia (79 unique partners across 18 countries), suggesting they are sought after as a trusted contributor with specific translational and manufacturing capabilities. Their broad partner network and zero repeat-coordination indicate they serve as a go-to specialist that diverse consortia invite for ATMP expertise.

Extensive European network with 79 unique consortium partners across 18 countries, reflecting their reputation as a sought-after ATMP specialist. Their partnerships span academic, clinical, and industrial organizations across the advanced therapies ecosystem.

What sets them apart

As a UK Catapult centre specifically dedicated to cell and gene therapy, they occupy a rare niche: a publicly-backed translational body focused entirely on moving ATMPs from lab to clinic. Unlike universities that research or companies that manufacture, they sit in the middle — helping both sides navigate manufacturing scale-up, regulatory hurdles, and clinical translation. Their combination of hands-on manufacturing expertise with gene editing knowledge and public engagement capabilities is uncommon in a single organization.

Highlights from their portfolio

• RESHAPE
  Largest funding (EUR 1M+), represents their strategic pivot into CRISPR-based regulatory T cell immunotherapy with advanced preclinical models (humanized rodents, human-on-the-chip).
• AUTOSTEM
  Directly targets a major bottleneck in the field — automated, closed, scalable manufacturing systems for therapeutic stem cells.
• EuroGCT
  Pan-European communication consortium running until 2026, showing commitment to responsible public engagement around gene and cell therapies beyond just R&D.